Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: All cancers

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**23716**	**2789**	**11.9**	**8557**	**36.6**	**1380**	**5.9**	**14919**	**64.0**	**898**	**3.8**	**3763**	**16.0**
	Age at baseline	<18	5295	636	12.1	1771	33.9	59	1.1	3400	65.3	312	5.9	1044	19.8
		18-19	1964	254	13.0	704	36.4	32	1.6	1321	68.6	73	3.7	335	17.2
		20-24	5511	676	12.4	1918	35.2	177	3.2	3601	66.4	233	4.3	948	17.3
		25-29	5150	630	12.4	1988	39.2	412	8.1	3246	64.2	153	3.0	735	14.4
		30-34	3566	400	11.4	1379	39.4	415	11.8	2144	61.4	90	2.6	481	13.7
		35+	2230	193	8.8	797	36.4	285	13.0	1207	55.2	37	1.7	220	10.0
	Years since diagnosis	5-9	2391	281	11.9	820	35.1	119	5.0	1372	58.9	158	6.7	460	19.4
		10-14	7681	1112	14.6	2926	38.6	519	6.8	4928	65.2	303	4.0	1294	17.0
		15-19	7592	873	11.6	2780	37.2	437	5.8	4903	65.7	244	3.2	1272	16.9
		20+	6052	523	8.7	2031	34.1	305	5.1	3716	62.5	193	3.2	737	12.3
	Age at diagnosis	<1	1789	125	7.0	152	8.6	11	0.6	784	44.3	59	3.3	382	21.5
		1-4	7646	914	12.1	2904	38.6	52	0.7	5448	72.5	398	5.2	1321	17.4
		5-9	5313	632	12.0	2047	39.1	180	3.4	3514	67.3	201	3.8	796	15.1
		10-14	5026	678	13.6	2045	41.3	508	10.2	3089	62.4	169	3.4	741	14.9
		15-20	3942	440	11.3	1409	36.6	629	16.2	2084	54.2	71	1.8	523	13.5
Males	**All cases**		**12555**	**1528**	**12.3**	**4650**	**37.6**	**706**	**5.7**	**7937**	**64.4**	**492**	**4.0**	**2045**	**16.4**
	Age at baseline	<18	2844	340	12.1	937	33.5	40	1.4	1786	64.0	164	5.8	589	20.8
		18-19	1013	143	14.2	389	38.9	24	2.4	678	67.9	39	3.9	171	17.0
		20-24	2866	346	12.2	1022	36.1	111	3.9	1875	66.5	114	4.0	487	17.1
		25-29	2820	376	13.5	1135	40.9	208	7.4	1804	65.2	86	3.1	416	14.9
		30-34	1889	217	11.6	749	40.4	208	11.2	1157	62.5	61	3.3	266	14.3
		35+	1123	106	9.6	418	37.9	115	10.4	637	57.7	28	2.5	116	10.5
	Years since diagnosis	5-9	1331	156	11.9	453	34.8	67	5.1	732	56.6	83	6.3	261	19.8
		10-14	4084	613	15.1	1602	39.8	256	6.3	2638	65.7	162	4.0	712	17.6
		15-19	3944	467	12.0	1473	37.9	228	5.8	2587	66.7	136	3.5	686	17.6
		20+	3196	292	9.2	1122	35.7	155	4.9	1980	63.1	111	3.5	386	12.2
	Age at diagnosis	<1	907	60	6.7	67	7.5	4	0.4	383	42.7	28	3.1	201	22.3
		1-4	3967	503	12.8	1509	38.6	35	0.9	2785	71.4	207	5.3	712	18.1
		5-9	2975	369	12.5	1192	40.8	136	4.6	1980	67.9	109	3.7	441	15.0
		10-14	2625	342	13.1	1124	43.4	256	9.8	1661	64.2	100	3.8	391	15.0
		15-20	2081	254	12.4	758	37.2	275	13.4	1128	55.5	48	2.3	300	14.6
Females	**All cases**		**11161**	**1261**	**11.4**	**3907**	**35.5**	**674**	**6.1**	**6982**	**63.7**	**406**	**3.7**	**1718**	**15.5**
	Age at baseline	<18	2451	296	12.2	834	34.4	19	0.8	1614	66.8	148	6.1	455	18.6
		18-19	951	111	11.8	315	33.8	8	0.8	643	69.2	34	3.6	164	17.4
		20-24	2645	330	12.6	896	34.3	66	2.5	1726	66.2	119	4.5	461	17.5
		25-29	2330	254	11.0	853	37.1	204	8.8	1442	63.1	67	2.9	319	13.8
		30-34	1677	183	11.0	630	38.3	207	12.5	987	60.1	29	1.7	215	13.0
		35+	1107	87	8.0	379	34.9	170	15.6	570	52.6	9	0.8	104	9.6
	Years since diagnosis	5-9	1060	125	12.0	367	35.4	52	5.0	640	61.8	75	7.1	199	19.0
		10-14	3597	499	14.0	1324	37.3	263	7.4	2290	64.7	141	3.9	582	16.3
		15-19	3648	406	11.2	1307	36.3	209	5.8	2316	64.6	108	3.0	586	16.2
		20+	2856	231	8.2	909	32.4	150	5.3	1736	61.9	82	2.9	351	12.4
	Age at diagnosis	<1	882	65	7.4	85	9.7	7	0.8	401	45.9	31	3.5	181	20.6
		1-4	3679	411	11.3	1395	38.5	17	0.5	2663	73.7	191	5.2	609	16.7
		5-9	2338	263	11.3	855	37.0	44	1.9	1534	66.4	92	4.0	355	15.3
		10-14	2401	336	14.1	921	38.9	252	10.6	1428	60.5	69	2.9	350	14.7
		15-20	1861	186	10.2	651	35.8	354	19.4	956	52.8	23	1.3	223	12.2

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: All leukemias

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**7302**	**1720**	**23.8**	**5207**	**73.0**	**17**	**0.2**	**5599**	**78.4**	**674**	**9.3**	**1528**	**21.1**
	Age at baseline	<18	2099	475	22.9	1500	73.4	6	0.3	1602	78.4	219	10.5	482	23.1
		18-19	769	188	24.6	560	74.8	2	0.3	604	80.6	55	7.2	143	18.7
		20-24	1799	433	24.3	1324	75.0	5	0.3	1422	80.5	191	10.7	350	19.6
		25-29	1471	356	24.4	1037	71.8	3	0.2	1121	77.4	119	8.2	304	20.8
		30-34	779	180	23.7	523	69.8	1	0.1	572	76.1	62	8.1	161	21.1
		35+	385	88	23.1	263	69.8	.	.	278	73.5	28	7.4	88	23.2
	Years since diagnosis	5-9	906	181	20.4	557	63.7	1	0.1	591	67.5	111	12.4	194	21.6
		10-14	2444	673	27.9	1852	77.6	6	0.2	1966	82.3	234	9.6	586	24.2
		15-19	2246	543	24.4	1620	73.6	7	0.3	1760	79.9	187	8.4	426	19.1
		20+	1706	323	19.1	1178	70.7	3	0.2	1282	76.8	142	8.4	322	19.1
	Age at diagnosis	<1	233	77	33.6	118	51.8	1	0.4	162	70.7	19	8.2	130	56.3
		1-4	3449	719	21.0	2540	75.3	10	0.3	2713	80.5	314	9.2	616	18.0
		5-9	1767	398	22.8	1282	74.5	4	0.2	1362	79.0	160	9.1	327	18.7
		10-14	1216	366	30.3	857	71.9	2	0.2	925	77.3	132	10.9	297	24.6
		15-20	637	160	25.7	410	66.6	.	.	437	70.8	49	7.9	158	25.3
Males	**All cases**		**3855**	**934**	**24.5**	**2687**	**71.5**	**10**	**0.3**	**2902**	**77.1**	**366**	**9.6**	**808**	**21.2**
	Age at baseline	<18	1137	254	22.6	760	69.0	3	0.3	813	73.8	119	10.5	255	22.6
		18-19	410	108	26.4	286	71.1	2	0.5	310	77.1	27	6.6	83	20.3
		20-24	895	213	24.0	648	73.6	2	0.2	704	80.0	94	10.6	169	19.0
		25-29	788	208	26.7	562	73.0	2	0.3	607	78.6	66	8.5	161	20.7
		30-34	411	93	23.4	276	70.1	1	0.3	306	77.5	39	9.8	90	22.6
		35+	214	58	27.4	155	73.8	.	.	162	76.8	21	10.0	50	23.7
	Years since diagnosis	5-9	510	102	20.2	286	58.0	.	.	303	61.5	56	11.1	103	20.3
		10-14	1300	367	28.6	966	76.2	3	0.2	1025	80.9	126	9.8	314	24.4
		15-19	1138	282	25.1	805	72.5	5	0.4	888	79.7	101	9.0	224	19.9
		20+	907	183	20.4	630	71.0	2	0.2	686	77.3	83	9.3	167	18.7
	Age at diagnosis	<1	111	36	33.3	57	53.3	.	.	80	74.8	11	10.1	60	55.0
		1-4	1822	394	21.8	1275	71.5	6	0.3	1371	76.8	167	9.2	335	18.5
		5-9	942	224	24.2	669	73.3	3	0.3	714	78.2	84	9.0	169	18.2
		10-14	596	180	30.5	431	74.1	1	0.2	467	79.8	71	12.0	145	24.6
		15-20	384	100	26.7	255	68.5	.	.	270	72.4	33	8.8	99	26.3
Females	**All cases**		**3447**	**786**	**23.0**	**2520**	**74.8**	**7**	**0.2**	**2697**	**79.9**	**308**	**9.0**	**720**	**21.0**
	Age at baseline	<18	962	221	23.3	740	78.6	3	0.3	789	83.8	100	10.4	227	23.7
		18-19	359	80	22.5	274	79.0	.	.	294	84.7	28	7.9	60	16.9
		20-24	904	220	24.6	676	76.4	3	0.3	718	80.9	97	10.8	181	20.2
		25-29	683	148	21.8	475	70.4	1	0.1	514	76.0	53	7.8	143	21.0
		30-34	368	87	24.0	247	69.6	.	.	266	74.5	23	6.3	71	19.5
		35+	171	30	17.8	108	64.7	.	.	116	69.5	7	4.1	38	22.6
	Years since diagnosis	5-9	396	79	20.6	271	70.9	1	0.3	288	75.2	55	14.0	91	23.2
		10-14	1144	306	27.0	886	79.0	3	0.3	941	83.9	108	9.5	272	23.9
		15-19	1108	261	23.7	815	74.8	2	0.2	872	80.1	86	7.8	202	18.3
		20+	799	140	17.7	548	70.3	1	0.1	596	76.2	59	7.4	155	19.6
	Age at diagnosis	<1	122	41	33.9	61	50.4	1	0.8	82	67.2	8	6.6	70	57.4
		1-4	1627	325	20.2	1265	79.7	4	0.2	1342	84.5	147	9.1	281	17.4
		5-9	825	174	21.3	613	75.9	1	0.1	648	80.0	76	9.3	158	19.3

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: All leukemias

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	620	186	30.2	426	69.8	1	0.2	458	74.8	61	9.9	152	24.6
		15-20	253	60	24.3	155	63.5	.	.	167	68.4	16	6.5	59	23.9

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**6109**	**1334**	**22.1**	**4888**	**81.9**	**15**	**0.2**	**5173**	**86.6**	**657**	**10.8**	**865**	**14.3**
	Age at baseline	<18	1814	374	20.9	1440	81.5	5	0.3	1491	84.4	213	11.8	291	16.1
		18-19	666	153	23.1	536	82.8	2	0.3	561	86.7	54	8.2	91	13.7
		20-24	1532	337	22.2	1250	83.0	4	0.3	1325	88.0	185	12.2	197	12.9
		25-29	1217	271	22.4	967	80.9	3	0.2	1038	86.6	117	9.7	166	13.7
		30-34	604	134	22.7	469	80.7	1	0.2	515	88.3	61	10.3	79	13.3
		35+	276	65	23.8	226	83.7	.	.	243	90.0	27	9.9	41	15.1
	Years since diagnosis	5-9	778	145	19.0	529	70.4	1	0.1	545	72.6	104	13.5	127	16.5
		10-14	2048	545	26.9	1760	87.9	5	0.2	1835	91.7	229	11.3	360	17.7
		15-19	1853	410	22.3	1513	83.4	7	0.4	1619	89.2	186	10.1	202	11.0
		20+	1430	234	16.5	1086	77.7	2	0.1	1174	83.8	138	9.7	176	12.4
	Age at diagnosis	<1	128	36	28.6	99	79.2	1	0.8	116	92.1	16	12.6	54	42.5
		1-4	3055	580	19.2	2434	81.6	8	0.3	2549	85.4	309	10.2	374	12.3
		5-9	1545	312	20.5	1223	81.1	4	0.3	1291	85.6	157	10.3	200	13.1
		10-14	949	284	30.0	786	84.1	2	0.2	842	89.8	128	13.5	158	16.7
		15-20	432	122	29.1	346	83.6	.	.	375	90.6	47	11.2	79	18.8
Males	**All cases**		**3252**	**739**	**23.0**	**2527**	**79.6**	**9**	**0.3**	**2691**	**84.7**	**356**	**11.0**	**470**	**14.6**
	Age at baseline	<18	982	201	20.7	728	76.6	2	0.2	758	79.7	116	11.9	150	15.4
		18-19	358	87	24.4	275	78.6	2	0.6	288	82.3	27	7.6	52	14.6
		20-24	762	171	22.6	609	81.0	2	0.3	652	86.8	89	11.8	96	12.7
		25-29	665	166	25.2	530	81.3	2	0.3	569	87.0	65	9.8	94	14.2
		30-34	324	69	22.0	250	80.4	1	0.3	277	88.8	39	12.4	53	16.9
		35+	161	45	28.1	135	84.9	.	.	147	92.5	20	12.6	25	15.7
	Years since diagnosis	5-9	439	84	19.3	270	63.7	.	.	282	66.5	52	12.0	67	15.4
		10-14	1098	300	27.6	921	86.0	2	0.2	956	89.3	122	11.2	192	17.6
		15-19	950	217	23.1	753	81.1	5	0.5	817	87.8	101	10.8	118	12.6
		20+	765	138	18.2	583	77.6	2	0.3	636	84.6	81	10.7	93	12.3
	Age at diagnosis	<1	64	15	23.8	50	80.6	.	.	59	95.2	10	15.9	27	42.9
		1-4	1603	320	20.1	1220	77.8	5	0.3	1285	82.0	164	10.3	193	12.1
		5-9	833	184	22.4	641	79.1	3	0.4	683	84.3	83	10.1	113	13.7
		10-14	483	143	29.7	399	83.8	1	0.2	431	90.2	68	14.1	84	17.5
		15-20	269	77	29.5	217	83.8	.	.	233	90.0	31	11.9	53	20.2
Females	**All cases**		**2857**	**595**	**21.1**	**2361**	**84.6**	**6**	**0.2**	**2482**	**88.9**	**301**	**10.6**	**395**	**13.9**
	Age at baseline	<18	832	173	21.1	712	87.4	3	0.4	733	89.9	97	11.7	141	17.0
		18-19	308	66	21.6	261	87.9	.	.	273	91.9	27	8.9	39	12.8
		20-24	770	166	21.8	641	85.0	2	0.3	673	89.3	96	12.5	101	13.2
		25-29	552	105	19.1	437	80.3	1	0.2	469	86.1	52	9.5	72	13.1
		30-34	280	65	23.5	219	81.1	.	.	238	87.8	22	7.9	26	9.4
		35+	115	20	17.7	91	82.0	.	.	96	86.5	7	6.2	16	14.2
	Years since diagnosis	5-9	339	61	18.7	259	79.2	1	0.3	263	80.4	52	15.4	60	17.9
		10-14	950	245	26.0	839	90.0	3	0.3	879	94.3	107	11.3	168	17.8
		15-19	903	193	21.5	760	85.9	2	0.2	802	90.6	85	9.4	84	9.3
		20+	665	96	14.6	503	77.7	.	.	538	82.9	57	8.6	83	12.6
	Age at diagnosis	<1	64	21	33.3	49	77.8	1	1.6	57	89.1	6	9.4	27	42.2
		1-4	1452	260	18.1	1214	85.7	3	0.2	1264	89.3	145	10.0	181	12.5
		5-9	712	128	18.2	582	83.4	1	0.1	608	87.1	74	10.5	87	12.3
		10-14	466	141	30.4	387	84.3	1	0.2	411	89.3	60	12.9	74	15.9
		15-20	163	45	28.5	129	83.2	.	.	142	91.6	16	10.1	26	16.4

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**882**	**335**	**38.5**	**186**	**21.6**	**2**	**0.2**	**315**	**36.4**	**7**	**0.8**	**587**	**67.3**
	Age at baseline	<18	225	94	42.3	37	16.9	1	0.4	90	41.1	3	1.3	172	77.1
		18-19	82	28	34.6	16	19.8	.	.	35	43.2	1	1.2	46	56.8
		20-24	193	76	39.6	39	20.7	1	0.5	62	32.8	3	1.6	136	70.8
		25-29	188	77	41.4	45	24.1	.	.	65	34.8	.	.	119	64.0
		30-34	121	42	35.6	30	25.6	.	.	39	33.3	.	.	73	61.3
		35+	73	18	25.0	19	26.8	.	.	24	33.3	.	.	41	57.7
	Years since diagnosis	5-9	81	31	38.8	15	19.2	.	.	36	46.2	4	5.0	58	72.5
		10-14	307	117	38.6	54	17.9	1	0.3	106	35.1	2	0.7	203	66.8
		15-19	304	112	37.1	73	24.3	.	.	105	34.9	.	.	201	66.3
		20+	190	75	40.3	44	23.9	1	0.5	68	37.0	1	0.5	125	67.6
	Age at diagnosis	<1	90	39	43.8	14	15.7	.	.	41	46.1	3	3.4	69	77.5
		1-4	301	118	39.7	59	19.9	2	0.7	116	39.2	1	0.3	216	72.5
		5-9	166	70	42.4	33	20.6	.	.	46	28.6	2	1.2	112	67.9
		10-14	186	78	42.9	42	23.2	.	.	67	37.0	.	.	120	65.9
		15-20	139	30	21.7	38	27.7	.	.	45	32.6	1	0.7	70	50.7
Males	**All cases**		**430**	**155**	**36.6**	**79**	**18.9**	**1**	**0.2**	**140**	**33.4**	**3**	**0.7**	**293**	**69.1**
	Age at baseline	<18	122	48	40.0	17	14.3	1	0.8	42	35.3	1	0.8	95	79.2
		18-19	42	16	38.1	8	19.0	.	.	18	42.9	.	.	27	64.3
		20-24	92	28	30.4	18	20.2	.	.	29	32.6	2	2.2	61	66.3
		25-29	82	35	43.8	17	21.0	.	.	26	32.1	.	.	56	70.0
		30-34	58	20	35.7	12	21.8	.	.	18	32.7	.	.	33	57.9
		35+	34	8	24.2	7	21.9	.	.	7	21.2	.	.	21	63.6
	Years since diagnosis	5-9	47	14	29.8	8	17.8	.	.	15	33.3	2	4.3	31	66.0
		10-14	152	58	38.9	21	14.0	1	0.7	53	35.3	1	0.7	110	73.8
		15-19	141	50	35.7	34	24.6	.	.	49	35.3	.	.	93	66.0
		20+	90	33	37.9	16	18.8	.	.	23	27.1	.	.	59	67.8
	Age at diagnosis	<1	39	19	50.0	5	13.2	.	.	18	47.4	1	2.6	29	76.3
		1-4	165	58	35.6	28	17.2	1	0.6	57	35.0	.	.	124	76.1
		5-9	76	29	38.7	13	18.1	.	.	16	22.2	1	1.3	47	62.7
		10-14	75	33	45.2	14	19.4	.	.	24	33.3	.	.	54	74.0
		15-20	75	16	21.6	19	26.0	.	.	25	33.8	1	1.3	39	52.0
Females	**All cases**		**452**	**180**	**40.2**	**107**	**24.0**	**1**	**0.2**	**175**	**39.2**	**4**	**0.9**	**294**	**65.6**
	Age at baseline	<18	103	46	45.1	20	20.0	.	.	48	48.0	2	1.9	77	74.8
		18-19	40	12	30.8	8	20.5	.	.	17	43.6	1	2.6	19	48.7
		20-24	101	48	48.0	21	21.2	1	1.0	33	33.0	1	1.0	75	75.0
		25-29	106	42	39.6	28	26.4	.	.	39	36.8	.	.	63	59.4
		30-34	63	22	35.5	18	29.0	.	.	21	33.9	.	.	40	64.5
		35+	39	10	25.6	12	30.8	.	.	17	43.6	.	.	20	52.6
	Years since diagnosis	5-9	34	17	51.5	7	21.2	.	.	21	63.6	2	6.1	27	81.8
		10-14	155	59	38.3	33	21.9	.	.	53	34.9	1	0.6	93	60.0
		15-19	163	62	38.3	39	24.1	.	.	56	34.6	.	.	108	66.7
		20+	100	42	42.4	28	28.3	1	1.0	45	45.5	1	1.0	66	67.3
	Age at diagnosis	<1	51	20	39.2	9	17.6	.	.	23	45.1	2	3.9	40	78.4
		1-4	136	60	44.8	31	23.3	1	0.7	59	44.4	1	0.7	92	68.1
		5-9	90	41	45.6	20	22.7	.	.	30	33.7	1	1.1	65	72.2
		10-14	111	45	41.3	28	25.7	.	.	43	39.4	.	.	66	60.6
		15-20	64	14	21.9	19	29.7	.	.	20	31.3	.	.	31	49.2

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**4211**	**283**	**6.8**	**189**	**4.6**	**6**	**0.1**	**1245**	**30.1**	**10**	**0.2**	**409**	**9.8**
	Age at baseline	<18	891	64	7.3	54	6.1	3	0.3	338	38.3	3	0.3	130	14.7
		18-19	349	23	6.8	14	4.1	.	.	127	37.8	1	0.3	53	15.6
		20-24	1103	71	6.5	48	4.4	.	.	344	31.8	4	0.4	124	11.4
		25-29	1029	70	6.9	54	5.3	3	0.3	291	28.8	1	0.1	62	6.1
		30-34	586	35	6.0	14	2.4	.	.	112	19.4	1	0.2	32	5.5
		35+	253	20	8.1	5	2.0	.	.	33	13.4	.	.	8	3.2
	Years since diagnosis	5-9	430	29	6.9	39	9.3	.	.	147	35.0	3	0.7	60	14.2
		10-14	1427	90	6.4	44	3.1	5	0.4	433	30.8	.	.	107	7.6
		15-19	1335	103	7.8	62	4.7	1	0.1	396	30.3	6	0.5	170	13.0
		20+	1019	61	6.0	44	4.4	.	.	269	26.8	1	0.1	72	7.1
	Age at diagnosis	<1	206	13	6.3	14	6.8	1	0.5	102	49.8	1	0.5	47	22.9
		1-4	1231	83	6.8	57	4.7	1	0.1	445	36.8	5	0.4	190	15.6
		5-9	1331	92	7.0	71	5.4	1	0.1	404	30.9	3	0.2	98	7.5
		10-14	1005	69	6.9	36	3.6	3	0.3	231	23.3	1	0.1	57	5.7
		15-20	438	26	6.1	11	2.6	.	.	63	14.9	.	.	17	4.0
Males	**All cases**		**2292**	**166**	**7.4**	**106**	**4.7**	**3**	**0.1**	**729**	**32.5**	**5**	**0.2**	**235**	**10.4**
	Age at baseline	<18	494	38	7.8	31	6.4	1	0.2	200	41.1	1	0.2	83	17.0
		18-19	177	14	8.1	6	3.5	.	.	67	39.2	1	0.6	25	14.5
		20-24	590	41	7.1	28	4.8	.	.	206	35.6	2	0.3	75	12.9
		25-29	584	48	8.3	30	5.2	2	0.3	182	31.7	1	0.2	31	5.4
		30-34	312	16	5.2	7	2.3	.	.	53	17.4	.	.	16	5.2
		35+	135	9	7.0	4	3.1	.	.	21	16.3	.	.	5	3.9
	Years since diagnosis	5-9	244	18	7.6	22	9.2	.	.	80	33.8	1	0.4	36	15.1
		10-14	768	54	7.1	30	4.0	2	0.3	261	34.5	.	.	63	8.3
		15-19	726	58	8.1	31	4.4	1	0.1	240	33.9	4	0.6	98	13.8
		20+	554	36	6.6	23	4.2	.	.	148	27.4	.	.	38	7.0
	Age at diagnosis	<1	121	10	8.3	5	4.2	.	.	60	50.0	.	.	31	25.8
		1-4	652	48	7.5	31	4.8	.	.	251	39.2	3	0.5	108	16.8
		5-9	741	61	8.3	41	5.6	1	0.1	251	34.6	2	0.3	59	8.1
		10-14	531	38	7.3	24	4.6	2	0.4	128	24.5	.	.	28	5.4
		15-20	247	9	3.8	5	2.1	.	.	39	16.5	.	.	9	3.8
Females	**All cases**		**1919**	**117**	**6.2**	**83**	**4.4**	**3**	**0.2**	**516**	**27.3**	**5**	**0.3**	**174**	**9.2**
	Age at baseline	<18	397	26	6.6	23	5.8	2	0.5	138	34.9	2	0.5	47	11.9
		18-19	172	9	5.4	8	4.8	.	.	60	36.4	.	.	28	16.8
		20-24	513	30	5.9	20	4.0	.	.	138	27.4	2	0.4	49	9.7
		25-29	445	22	5.0	24	5.5	1	0.2	109	24.9	.	.	31	7.1
		30-34	274	19	7.0	7	2.6	.	.	59	21.7	1	0.4	16	5.9
		35+	118	11	9.3	1	0.8	.	.	12	10.2	.	.	3	2.5
	Years since diagnosis	5-9	186	11	6.0	17	9.3	.	.	67	36.6	2	1.1	24	13.0
		10-14	659	36	5.5	14	2.1	3	0.5	172	26.4	.	.	44	6.7
		15-19	609	45	7.5	31	5.2	.	.	156	26.2	2	0.3	72	12.0
		20+	465	25	5.4	21	4.5	.	.	121	26.2	1	0.2	34	7.3
	Age at diagnosis	<1	85	3	3.5	9	10.6	1	1.2	42	49.4	1	1.2	16	18.8
		1-4	579	35	6.1	26	4.6	1	0.2	194	34.2	2	0.3	82	14.3
		5-9	590	31	5.3	30	5.1	.	.	153	26.3	1	0.2	39	6.7
		10-14	474	31	6.6	12	2.5	1	0.2	103	21.9	1	0.2	29	6.2
		15-20	191	17	9.0	6	3.2	.	.	24	12.8	.	.	8	4.3

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Astrocytomas

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2528**	**132**	**5.3**	**59**	**2.4**	**2**	**0.1**	**424**	**17.0**	**7**	**0.3**	**90**	**3.6**
	Age at baseline	<18	493	26	5.3	17	3.5	2	0.4	133	27.1	2	0.4	32	6.5
		18-19	202	9	4.6	6	3.0	.	.	54	27.8	.	.	11	5.6
		20-24	668	38	5.8	16	2.4	.	.	107	16.3	3	0.5	30	4.5
		25-29	636	33	5.3	13	2.1	.	.	87	13.9	1	0.2	15	2.4
		30-34	360	16	4.5	5	1.4	.	.	32	9.0	1	0.3	2	0.6
		35+	169	10	6.0	2	1.2	.	.	11	6.6	.	.	.	.
	Years since diagnosis	5-9	220	10	4.6	14	6.4	.	.	50	22.9	2	0.9	14	6.4
		10-14	840	46	5.5	13	1.6	2	0.2	157	19.0	.	.	19	2.3
		15-19	784	48	6.2	17	2.2	.	.	120	15.6	4	0.5	36	4.7
		20+	684	28	4.1	15	2.2	.	.	97	14.4	1	0.1	21	3.1
	Age at diagnosis	<1	145	10	6.9	9	6.2	1	0.7	68	46.9	1	0.7	24	16.6
		1-4	748	35	4.7	16	2.2	.	.	168	22.9	2	0.3	42	5.7
		5-9	753	34	4.6	18	2.4	1	0.1	99	13.3	3	0.4	15	2.0
		10-14	603	37	6.2	11	1.8	.	.	61	10.2	1	0.2	7	1.2
		15-20	279	16	5.9	5	1.8	.	.	28	10.3	.	.	2	0.7
Males	**All cases**		**1315**	**74**	**5.7**	**31**	**2.4**	**1**	**0.1**	**245**	**18.9**	**3**	**0.2**	**52**	**4.0**
	Age at baseline	<18	258	15	5.9	11	4.3	1	0.4	78	30.6	.	.	22	8.6
		18-19	102	5	5.0	3	3.0	.	.	31	31.3	.	.	5	5.0
		20-24	329	18	5.5	7	2.1	.	.	62	19.0	2	0.6	19	5.8
		25-29	356	24	6.8	7	2.0	.	.	54	15.4	1	0.3	5	1.4
		30-34	181	7	3.9	1	0.6	.	.	12	6.7	.	.	1	0.6
		35+	89	5	5.7	2	2.3	.	.	8	9.2	.	.	.	.
	Years since diagnosis	5-9	118	4	3.4	7	5.9	.	.	27	22.9	.	.	7	5.9
		10-14	438	26	6.0	11	2.5	1	0.2	97	22.5	.	.	14	3.2
		15-19	396	27	6.9	7	1.8	.	.	68	17.5	3	0.8	18	4.6
		20+	363	17	4.7	6	1.7	.	.	53	14.8	.	.	13	3.6
	Age at diagnosis	<1	81	8	9.9	4	4.9	.	.	40	49.4	.	.	19	23.5
		1-4	378	20	5.4	9	2.4	.	.	94	25.3	1	0.3	25	6.7
		5-9	397	23	5.9	9	2.3	1	0.3	62	15.9	2	0.5	5	1.3
		10-14	304	17	5.6	7	2.3	.	.	31	10.3	.	.	2	0.7
		15-20	155	6	3.9	2	1.3	.	.	18	11.8	.	.	1	0.7
Females	**All cases**		**1213**	**58**	**4.8**	**28**	**2.3**	**1**	**0.1**	**179**	**15.0**	**4**	**0.3**	**38**	**3.2**
	Age at baseline	<18	235	11	4.7	6	2.6	1	0.4	55	23.4	2	0.9	10	4.3
		18-19	100	4	4.1	3	3.1	.	.	23	24.2	.	.	6	6.2
		20-24	339	20	6.0	9	2.7	.	.	45	13.6	1	0.3	11	3.3
		25-29	280	9	3.3	6	2.2	.	.	33	12.0	.	.	10	3.6
		30-34	179	9	5.1	4	2.2	.	.	20	11.3	1	0.6	1	0.6
		35+	80	5	6.3	.	.	.	.	3	3.8	.	.	.	.
	Years since diagnosis	5-9	102	6	6.0	7	7.0	.	.	23	23.0	2	2.0	7	7.0
		10-14	402	20	5.0	2	0.5	1	0.3	60	15.2	.	.	5	1.3
		15-19	388	21	5.5	10	2.6	.	.	52	13.7	1	0.3	18	4.7
		20+	321	11	3.4	9	2.8	.	.	44	13.8	1	0.3	8	2.5
	Age at diagnosis	<1	64	2	3.1	5	7.8	1	1.6	28	43.8	1	1.6	5	7.8
		1-4	370	15	4.1	7	1.9	.	.	74	20.4	1	0.3	17	4.7
		5-9	356	11	3.1	9	2.5	.	.	37	10.5	1	0.3	10	2.8

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Astrocytomas

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	299	20	6.8	4	1.3	.	.	30	10.1	1	0.3	5	1.7
		15-20	124	10	8.3	3	2.5	.	.	10	8.3	.	.	1	0.8

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Medulloblastoma/PNET

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**983**	**106**	**11.0**	**99**	**10.3**	**1**	**0.1**	**664**	**69.0**	**3**	**0.3**	**218**	**22.5**
	Age at baseline	<18	233	23	10.0	26	11.4	.	.	153	66.8	1	0.4	62	27.0
		18-19	77	9	12.2	5	6.8	.	.	51	68.9	1	1.4	23	31.1
		20-24	276	28	10.3	25	9.2	.	.	203	74.9	1	0.4	69	25.4
		25-29	236	30	12.8	31	13.3	1	0.4	169	72.8	.	.	34	14.6
		30-34	127	14	11.1	9	7.3	.	.	72	58.1	.	.	25	19.8
		35+	34	2	6.3	3	9.4	.	.	16	50.0	.	.	5	15.6
	Years since diagnosis	5-9	120	14	12.2	19	16.7	.	.	73	63.5	1	0.9	32	27.6
		10-14	334	31	9.4	23	7.0	1	0.3	236	71.5	.	.	62	18.8
		15-19	325	40	12.5	39	12.2	.	.	219	68.9	2	0.6	87	27.2
		20+	204	21	10.4	18	9.0	.	.	136	68.3	.	.	37	18.4
	Age at diagnosis	<1	23	1	4.5	2	9.1	.	.	17	77.3	.	.	14	63.6
		1-4	280	31	11.2	26	9.5	.	.	198	72.3	3	1.1	87	31.5
		5-9	402	49	12.3	44	11.1	.	.	272	68.7	.	.	69	17.3
		10-14	220	21	9.7	23	10.7	1	0.5	150	69.4	.	.	36	16.7
		15-20	58	4	7.3	4	7.4	.	.	27	50.0	.	.	12	21.8
Males	**All cases**		**600**	**68**	**11.6**	**60**	**10.3**	**.**	**.**	**403**	**69.1**	**2**	**0.3**	**136**	**23.2**
	Age at baseline	<18	141	15	10.9	15	10.9	.	.	91	65.9	1	0.7	39	28.3
		18-19	44	5	11.9	2	4.9	.	.	28	66.7	1	2.4	14	33.3
		20-24	178	19	10.9	18	10.3	.	.	131	75.3	.	.	48	27.4
		25-29	145	20	13.9	17	11.9	.	.	110	77.5	.	.	19	13.3
		30-34	71	7	10.0	6	8.8	.	.	35	51.5	.	.	13	18.6
		35+	21	2	10.5	2	10.5	.	.	8	42.1	.	.	3	15.8
	Years since diagnosis	5-9	73	11	15.9	12	17.6	.	.	39	56.5	1	1.4	22	31.9
		10-14	197	20	10.3	15	7.7	.	.	145	74.7	.	.	37	19.1
		15-19	207	22	10.7	21	10.3	.	.	141	69.8	1	0.5	58	28.4
		20+	123	15	12.5	12	10.2	.	.	78	66.1	.	.	19	15.8
	Age at diagnosis	<1	16	.	.	1	6.7	.	.	11	73.3	.	.	7	46.7
		1-4	168	19	11.5	15	9.1	.	.	119	73.0	2	1.2	53	32.1
		5-9	256	32	12.6	27	10.7	.	.	174	69.0	.	.	49	19.4
		10-14	125	16	13.1	15	12.4	.	.	84	68.9	.	.	21	17.2
		15-20	35	1	3.1	2	6.5	.	.	15	48.4	.	.	6	18.8
Females	**All cases**		**383**	**38**	**10.0**	**39**	**10.3**	**1**	**0.3**	**261**	**68.9**	**1**	**0.3**	**82**	**21.6**
	Age at baseline	<18	92	8	8.8	11	12.1	.	.	62	68.1	.	.	23	25.0
		18-19	33	4	12.5	3	9.4	.	.	23	71.9	.	.	9	28.1
		20-24	98	9	9.3	7	7.2	.	.	72	74.2	1	1.0	21	21.6
		25-29	91	10	11.1	14	15.6	1	1.1	59	65.6	.	.	15	16.7
		30-34	56	7	12.5	3	5.4	.	.	37	66.1	.	.	12	21.4
		35+	13	.	.	1	7.7	.	.	8	61.5	.	.	2	15.4
	Years since diagnosis	5-9	47	3	6.5	7	15.2	.	.	34	73.9	.	.	10	21.3
		10-14	137	11	8.1	8	5.9	1	0.7	91	66.9	.	.	25	18.4
		15-19	118	18	15.5	18	15.5	.	.	78	67.2	1	0.9	29	25.0
		20+	81	6	7.4	6	7.4	.	.	58	71.6	.	.	18	22.2
	Age at diagnosis	<1	7	1	14.3	1	14.3	.	.	6	85.7	.	.	7	100.0
		1-4	112	12	10.8	11	9.9	.	.	79	71.2	1	0.9	34	30.6
		5-9	146	17	11.8	17	11.8	.	.	98	68.1	.	.	20	13.8

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Medulloblastoma/PNET

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	95	5	5.3	8	8.5	1	1.1	66	70.2	.	.	15	16.0
		15-20	23	3	13.0	2	8.7	.	.	12	52.2	.	.	6	26.1

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Hodgkin

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2839**	**141**	**5.0**	**1557**	**56.1**	**1308**	**46.9**	**1652**	**59.6**	**5**	**0.2**	**232**	**8.3**
	Age at baseline	<18	55	3	5.5	31	57.4	30	56.6	31	58.5	.	.	4	7.3
		18-19	54	1	1.9	30	55.6	28	51.9	32	59.3	.	.	4	7.4
		20-24	330	19	5.9	197	61.2	164	50.8	218	67.7	.	.	34	10.5
		25-29	734	37	5.1	462	64.5	399	55.3	454	63.5	2	0.3	63	8.7
		30-34	867	47	5.5	479	56.7	407	47.9	514	60.9	1	0.1	88	10.3
		35+	799	34	4.3	358	45.7	280	35.6	403	51.5	2	0.3	39	5.0
	Years since diagnosis	5-9	222	17	7.8	106	49.5	112	52.1	106	49.5	1	0.5	20	9.2
		10-14	866	53	6.2	507	59.9	485	57.1	525	62.1	1	0.1	85	9.9
		15-19	933	31	3.4	545	59.8	415	45.4	564	62.0	2	0.2	100	10.9
		20+	818	40	4.9	399	49.8	296	36.7	457	57.1	1	0.1	27	3.3
	Age at diagnosis	1-4	70	1	1.4	38	55.1	26	37.7	44	63.8	.	.	3	4.3
		5-9	356	12	3.4	214	61.0	170	48.3	225	64.3	.	.	23	6.5
		10-14	1029	59	5.8	635	63.0	492	48.5	683	67.8	1	0.1	83	8.2
		15-20	1384	69	5.1	670	49.8	620	45.9	700	52.1	4	0.3	123	9.0
Males	**All cases**		**1468**	**76**	**5.2**	**799**	**55.6**	**668**	**46.2**	**841**	**58.5**	**3**	**0.2**	**126**	**8.7**
	Age at baseline	<18	42	1	2.4	21	51.2	24	60.0	22	55.0	.	.	2	4.8
		18-19	43	1	2.3	24	55.8	22	51.2	25	58.1	.	.	3	7.0
		20-24	210	10	4.9	123	60.3	106	51.7	133	65.2	.	.	19	9.3
		25-29	402	25	6.3	244	62.2	200	50.4	240	61.2	1	0.3	38	9.6
		30-34	433	26	6.1	239	56.1	205	48.0	253	59.4	1	0.2	49	11.4
		35+	338	13	3.9	148	44.6	111	33.3	168	50.6	1	0.3	15	4.5
	Years since diagnosis	5-9	127	10	8.1	60	48.8	63	50.8	59	48.0	.	.	14	11.3
		10-14	440	28	6.4	251	58.2	238	55.0	259	60.2	1	0.2	44	10.1
		15-19	495	21	4.3	285	58.9	218	44.9	299	61.8	1	0.2	59	12.1
		20+	406	17	4.2	203	50.8	149	37.1	224	56.0	1	0.2	9	2.2
	Age at diagnosis	1-4	52	1	2.0	28	54.9	21	41.2	31	60.8	.	.	1	2.0
		5-9	261	5	1.9	157	61.3	129	50.2	160	62.7	.	.	14	5.4
		10-14	525	34	6.6	313	60.7	249	48.1	339	65.7	1	0.2	46	8.9
		15-20	630	36	5.8	301	48.9	269	43.5	311	50.6	2	0.3	65	10.5
Females	**All cases**		**1371**	**65**	**4.8**	**758**	**56.7**	**640**	**47.7**	**811**	**60.8**	**2**	**0.1**	**106**	**7.9**
	Age at baseline	<18	13	2	15.4	10	76.9	6	46.2	9	69.2	.	.	2	15.4
		18-19	11	.	.	6	54.5	6	54.5	7	63.6	.	.	1	9.1
		20-24	120	9	7.6	74	62.7	58	49.2	85	72.0	.	.	15	12.6
		25-29	332	12	3.6	218	67.3	199	61.2	214	66.3	1	0.3	25	7.6
		30-34	434	21	4.9	240	57.3	202	47.9	261	62.4	.	.	39	9.2
		35+	461	21	4.6	210	46.6	169	37.3	235	52.2	1	0.2	24	5.3
	Years since diagnosis	5-9	95	7	7.4	46	50.5	49	53.8	47	51.6	1	1.1	6	6.4
		10-14	426	25	6.0	256	61.5	247	59.2	266	63.9	.	.	41	9.8
		15-19	438	10	2.3	260	60.7	197	45.9	265	62.2	1	0.2	41	9.5
		20+	412	23	5.7	196	48.9	147	36.3	233	58.3	.	.	18	4.4
	Age at diagnosis	1-4	18	.	.	10	55.6	5	27.8	13	72.2	.	.	2	11.1
		5-9	95	7	7.4	57	60.0	41	43.2	65	68.4	.	.	9	9.5
		10-14	504	25	5.0	322	65.4	243	49.0	344	70.1	.	.	37	7.4
		15-20	754	33	4.5	369	50.5	351	47.9	389	53.4	2	0.3	58	7.8

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1933**	**252**	**13.1**	**1528**	**80.3**	**25**	**1.3**	**1762**	**92.4**	**84**	**4.4**	**343**	**17.9**
	Age at baseline	<18	200	16	8.0	168	85.3	3	1.5	175	88.8	11	5.5	34	17.1
		18-19	119	15	12.7	96	81.4	1	0.8	109	92.4	7	5.9	23	19.5
		20-24	409	63	15.4	330	81.5	6	1.5	380	93.8	14	3.4	74	18.1
		25-29	533	72	13.6	420	80.6	6	1.1	491	94.1	21	4.0	100	18.9
		30-34	443	65	14.7	347	78.9	6	1.4	413	93.9	24	5.4	85	19.2
		35+	229	21	9.3	167	74.9	3	1.3	194	86.6	7	3.1	27	11.9
	Years since diagnosis	5-9	132	10	7.6	104	79.4	.	.	108	82.4	11	8.3	20	15.2
		10-14	608	100	16.5	502	83.8	9	1.5	559	93.3	22	3.6	110	18.2
		15-19	665	99	15.0	534	81.3	13	2.0	629	95.7	27	4.1	147	22.3
		20+	528	43	8.2	388	75.0	3	0.6	466	89.8	24	4.6	66	12.6
	Age at diagnosis	<1	12	1	8.3	9	75.0	1	8.3	8	66.7	.	.	1	8.3
		1-4	320	33	10.4	248	79.7	6	1.9	291	93.3	15	4.7	66	20.8
		5-9	588	68	11.6	463	79.4	3	0.5	542	93.0	22	3.8	99	16.9
		10-14	604	81	13.5	504	84.3	8	1.3	567	94.8	32	5.3	102	16.9
		15-20	409	69	17.0	304	76.0	7	1.7	354	88.3	15	3.7	75	18.5
Males	**All cases**		**1304**	**155**	**12.0**	**1021**	**79.3**	**10**	**0.8**	**1185**	**91.9**	**61**	**4.7**	**224**	**17.3**
	Age at baseline	<18	138	8	5.8	118	87.4	1	0.7	122	90.4	10	7.3	26	19.0
		18-19	87	10	11.6	70	81.4	.	.	79	91.9	4	4.7	13	15.1
		20-24	268	41	15.3	216	80.9	2	0.7	250	93.6	11	4.1	47	17.5
		25-29	372	48	13.0	291	79.5	3	0.8	344	93.7	11	3.0	71	19.2
		30-34	291	38	13.1	219	75.8	2	0.7	266	92.0	19	6.6	50	17.2
		35+	148	10	6.8	107	73.8	2	1.4	124	84.9	6	4.1	17	11.6
	Years since diagnosis	5-9	99	8	8.1	80	81.6	.	.	83	84.7	11	11.1	15	15.2
		10-14	412	62	15.1	343	84.1	4	1.0	379	92.9	16	3.9	74	18.0
		15-19	433	58	13.5	344	80.0	4	0.9	412	95.8	17	3.9	92	21.3
		20+	360	27	7.6	254	72.2	2	0.6	311	87.9	17	4.8	43	12.0
	Age at diagnosis	<1	3	.	.	1	33.3	.	.	1	33.3	.	.	.	.
		1-4	215	20	9.4	164	78.8	2	0.9	194	92.8	9	4.2	44	20.7
		5-9	411	48	11.8	319	78.4	2	0.5	377	92.6	16	3.9	65	15.9
		10-14	412	47	11.4	349	84.7	2	0.5	390	94.7	25	6.1	69	16.7
		15-20	263	40	15.3	188	72.9	4	1.5	223	86.1	11	4.2	46	17.6
Females	**All cases**		**629**	**97**	**15.5**	**507**	**82.3**	**15**	**2.4**	**577**	**93.7**	**23**	**3.7**	**119**	**19.1**
	Age at baseline	<18	62	8	12.9	50	80.6	2	3.2	53	85.5	1	1.6	8	12.9
		18-19	32	5	15.6	26	81.3	1	3.1	30	93.8	3	9.4	10	31.3
		20-24	141	22	15.7	114	82.6	4	2.9	130	94.2	3	2.1	27	19.3
		25-29	161	24	15.1	129	83.2	3	1.9	147	94.8	10	6.3	29	18.2
		30-34	152	27	17.8	128	84.8	4	2.6	147	97.4	5	3.3	35	23.0
		35+	81	11	13.9	60	76.9	1	1.3	70	89.7	1	1.3	10	12.7
	Years since diagnosis	5-9	33	2	6.1	24	72.7	.	.	25	75.8	.	.	5	15.2
		10-14	196	38	19.5	159	83.2	5	2.6	180	94.2	6	3.1	36	18.5
		15-19	232	41	17.9	190	83.7	9	3.9	217	95.6	10	4.4	55	24.0
		20+	168	16	9.6	134	81.2	1	0.6	155	93.9	7	4.2	23	13.8
	Age at diagnosis	<1	9	1	11.1	8	88.9	1	11.1	7	77.8	.	.	1	11.1
		1-4	105	13	12.5	84	81.6	4	3.8	97	94.2	6	5.8	22	21.2
		5-9	177	20	11.3	144	81.8	1	0.6	165	93.8	6	3.4	34	19.2
		10-14	192	34	17.9	155	83.3	6	3.2	177	95.2	7	3.7	33	17.4
		15-20	146	29	20.1	116	81.7	3	2.1	131	92.3	4	2.8	29	20.1

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2087**	**24**	**1.2**	**17**	**0.8**	**9**	**0.4**	**1930**	**93.1**	**3**	**0.1**	**142**	**6.8**
	Age at baseline	<18	762	8	1.0	7	0.9	8	1.0	708	93.3	3	0.4	51	6.7
		18-19	276	3	1.1	2	0.7	1	0.4	259	94.5	.	.	21	7.6
		20-24	616	7	1.1	4	0.7	.	.	585	95.6	.	.	36	5.9
		25-29	347	4	1.2	4	1.2	.	.	304	88.9	.	.	27	7.8
		30-34	69	2	2.9	.	.	.	.	60	88.2	.	.	5	7.4
		35+	17	.	.	.	.	.	.	14	82.4	.	.	2	11.8
	Years since diagnosis	5-9	168	2	1.2	4	2.4	2	1.2	150	89.8	.	.	22	13.1
		10-14	674	8	1.2	4	0.6	7	1.0	633	94.5	3	0.4	41	6.1
		15-19	685	9	1.3	6	0.9	.	.	656	96.3	.	.	56	8.2
		20+	560	5	0.9	3	0.5	.	.	491	88.6	.	.	23	4.1
	Age at diagnosis	<1	305	2	0.7	4	1.3	2	0.7	253	83.8	1	0.3	10	3.3
		1-4	1270	12	0.9	4	0.3	5	0.4	1202	95.2	1	0.1	73	5.8
		5-9	436	7	1.6	7	1.6	2	0.5	410	94.7	1	0.2	45	10.3
		10-14	56	1	1.8	1	1.8	.	.	47	87.0	.	.	9	16.4
		15-20	20	2	10.0	1	5.0	.	.	18	90.0	.	.	5	25.0
Males	**All cases**		**924**	**11**	**1.2**	**6**	**0.7**	**6**	**0.7**	**845**	**92.0**	**.**	**.**	**67**	**7.3**
	Age at baseline	<18	370	4	1.1	3	0.8	6	1.6	343	93.2	.	.	31	8.4
		18-19	111	1	0.9	1	0.9	.	.	102	91.9	.	.	9	8.1
		20-24	255	3	1.2	1	0.4	.	.	241	95.3	.	.	10	3.9
		25-29	152	2	1.3	1	0.7	.	.	126	84.0	.	.	16	10.5
		30-34	29	1	3.4	.	.	.	.	26	89.7	.	.	1	3.4
		35+	7	.	.	.	.	.	.	7	100.0	.	.	.	.
	Years since diagnosis	5-9	75	1	1.3	1	1.3	2	2.7	66	89.2	.	.	14	18.7
		10-14	306	3	1.0	2	0.7	4	1.3	286	93.8	.	.	15	4.9
		15-19	292	3	1.0	2	0.7	.	.	279	95.9	.	.	26	8.9
		20+	251	4	1.6	1	0.4	.	.	214	86.3	.	.	12	4.8
	Age at diagnosis	<1	152	1	0.7	2	1.3	1	0.7	122	81.3	.	.	8	5.3
		1-4	567	6	1.1	1	0.2	4	0.7	532	94.3	.	.	34	6.0
		5-9	177	4	2.3	2	1.1	1	0.6	167	94.9	.	.	21	11.9
		10-14	20	.	.	1	5.0	.	.	16	80.0	.	.	2	10.0
		15-20	8	.	.	.	.	.	.	8	100.0	.	.	2	25.0
Females	**All cases**		**1163**	**13**	**1.1**	**11**	**0.9**	**3**	**0.3**	**1085**	**94.0**	**3**	**0.3**	**75**	**6.5**
	Age at baseline	<18	392	4	1.0	4	1.0	2	0.5	365	93.4	3	0.8	20	5.1
		18-19	165	2	1.2	1	0.6	1	0.6	157	96.3	.	.	12	7.3
		20-24	361	4	1.1	3	0.8	.	.	344	95.8	.	.	26	7.2
		25-29	195	2	1.0	3	1.5	.	.	178	92.7	.	.	11	5.7
		30-34	40	1	2.6	.	.	.	.	34	87.2	.	.	4	10.3
		35+	10	.	.	.	.	.	.	7	70.0	.	.	2	20.0
	Years since diagnosis	5-9	93	1	1.1	3	3.2	.	.	84	90.3	.	.	8	8.6
		10-14	368	5	1.4	2	0.5	3	0.8	347	95.1	3	0.8	26	7.1
		15-19	393	6	1.5	4	1.0	.	.	377	96.7	.	.	30	7.7
		20+	309	1	0.3	2	0.6	.	.	277	90.5	.	.	11	3.6
	Age at diagnosis	<1	153	1	0.7	2	1.3	1	0.7	131	86.2	1	0.7	2	1.3
		1-4	703	6	0.9	3	0.4	1	0.1	670	95.9	1	0.1	39	5.6
		5-9	259	3	1.2	5	1.9	1	0.4	243	94.6	1	0.4	24	9.3
		10-14	36	1	2.9	.	.	.	.	31	91.2	.	.	7	20.0
		15-20	12	2	16.7	1	8.3	.	.	10	83.3	.	.	3	25.0

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Neuroblastoma

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1811**	**64**	**3.6**	**15**	**0.8**	**6**	**0.3**	**463**	**25.9**	**111**	**6.2**	**485**	**27.0**
	Age at baseline	<18	890	39	4.4	6	0.7	6	0.7	224	25.5	71	8.0	243	27.5
		18-19	216	4	1.9	1	0.5	.	.	50	23.1	9	4.2	52	24.2
		20-24	511	14	2.8	5	1.0	.	.	130	25.8	21	4.1	151	29.8
		25-29	154	5	3.3	3	2.0	.	.	42	28.2	9	6.0	31	20.8
		30-34	34	1	3.1	.	.	.	.	17	53.1	1	3.1	6	18.8
		35+	6	1	16.7	.	.	.	.	.	.	.	.	2	33.3
	Years since diagnosis	5-9	152	7	4.7	1	0.7	2	1.3	53	35.6	28	18.7	55	36.7
		10-14	559	29	5.2	6	1.1	4	0.7	140	25.1	38	6.8	147	26.3
		15-19	594	15	2.5	1	0.2	.	.	142	24.3	20	3.4	167	28.4
		20+	506	13	2.6	7	1.4	.	.	128	25.9	25	5.0	116	23.3
	Age at diagnosis	<1	917	26	2.9	6	0.7	5	0.5	167	18.4	37	4.1	175	19.2
		1-4	713	28	4.0	9	1.3	1	0.1	234	33.3	59	8.4	245	34.8
		5-9	137	4	3.0	.	.	.	.	49	36.6	13	9.6	53	39.6
		10-14	27	3	11.5	.	.	.	.	8	30.8	1	3.8	5	19.2
		15-20	17	3	17.6	.	.	.	.	5	29.4	1	5.9	7	41.2
Males	**All cases**		**876**	**28**	**3.2**	**8**	**0.9**	**3**	**0.3**	**220**	**25.4**	**50**	**5.8**	**250**	**28.8**
	Age at baseline	<18	441	17	3.9	2	0.5	3	0.7	105	24.1	32	7.3	133	30.4
		18-19	94	1	1.1	1	1.1	.	.	25	26.6	6	6.4	22	23.4
		20-24	259	7	2.7	3	1.2	.	.	61	23.9	5	2.0	75	29.3
		25-29	66	2	3.1	2	3.1	.	.	19	29.7	6	9.4	17	26.6
		30-34	14	1	7.1	.	.	.	.	10	71.4	1	7.1	2	14.3
		35+	2	.	.	.	.	.	.	.	.	.	.	1	50.0
	Years since diagnosis	5-9	72	3	4.2	1	1.4	1	1.4	22	31.4	13	18.3	27	38.0
		10-14	275	10	3.6	2	0.7	2	0.7	65	23.7	16	5.8	84	30.5
		15-19	284	9	3.2	1	0.4	.	.	71	25.4	11	3.9	80	28.5
		20+	245	6	2.5	4	1.7	.	.	62	25.7	10	4.1	59	24.5
	Age at diagnosis	<1	472	11	2.3	2	0.4	3	0.6	79	16.8	17	3.6	93	19.8
		1-4	320	12	3.8	6	1.9	.	.	108	34.4	26	8.3	121	38.4
		5-9	68	3	4.5	.	.	.	.	30	45.5	5	7.5	32	47.8
		10-14	10	1	10.0	.	.	.	.	1	10.0	1	10.0	2	20.0
		15-20	6	1	16.7	.	.	.	.	2	33.3	1	16.7	2	33.3
Females	**All cases**		**935**	**36**	**3.9**	**7**	**0.8**	**3**	**0.3**	**243**	**26.4**	**61**	**6.6**	**235**	**25.4**
	Age at baseline	<18	449	22	4.9	4	0.9	3	0.7	119	26.9	39	8.7	110	24.7
		18-19	122	3	2.5	.	.	.	.	25	20.5	3	2.5	30	24.8
		20-24	252	7	2.8	2	0.8	.	.	69	27.7	16	6.4	76	30.3
		25-29	88	3	3.5	1	1.2	.	.	23	27.1	3	3.5	14	16.5
		30-34	20	.	.	.	.	.	.	7	38.9	.	.	4	22.2
		35+	4	1	25.0	.	.	.	.	.	.	.	.	1	25.0
	Years since diagnosis	5-9	80	4	5.1	.	.	1	1.3	31	39.2	15	19.0	28	35.4
		10-14	284	19	6.7	4	1.4	2	0.7	75	26.4	22	7.7	63	22.3
		15-19	310	6	2.0	.	.	.	.	71	23.4	9	2.9	87	28.3
		20+	261	7	2.7	3	1.2	.	.	66	26.0	15	5.8	57	22.3
	Age at diagnosis	<1	445	15	3.4	4	0.9	2	0.5	88	20.1	20	4.5	82	18.6
		1-4	393	16	4.1	3	0.8	1	0.3	126	32.5	33	8.5	124	31.9
		5-9	69	1	1.5	.	.	.	.	19	27.9	8	11.8	21	31.3

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Neuroblastoma

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	17	2	12.5	.	.	.	.	7	43.8	.	.	3	18.8
		15-20	11	2	18.2	.	.	.	.	3	27.3	.	.	5	45.5

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1596**	**82**	**5.2**	**25**	**1.6**	**7**	**0.4**	**1249**	**79.4**	**7**	**0.4**	**240**	**15.1**
	Age at baseline	<18	313	22	7.1	4	1.3	3	1.0	268	86.7	4	1.3	68	21.8
		18-19	115	8	7.0	1	0.9	.	.	100	87.7	1	0.9	20	17.5
		20-24	383	16	4.2	6	1.6	2	0.5	318	84.1	2	0.5	80	21.0
		25-29	354	20	5.7	5	1.4	1	0.3	279	80.2	.	.	38	10.8
		30-34	267	10	3.8	8	3.0	.	.	194	73.2	.	.	28	10.6
		35+	164	6	3.7	1	0.6	1	0.6	90	56.3	.	.	6	3.7
	Years since diagnosis	5-9	165	7	4.3	7	4.3	2	1.2	106	65.4	4	2.4	38	23.2
		10-14	473	44	9.3	3	0.6	3	0.6	363	77.9	3	0.6	78	16.6
		15-19	499	20	4.0	7	1.4	.	.	417	84.4	.	.	80	16.1
		20+	459	11	2.4	8	1.8	2	0.4	363	80.3	.	.	44	9.7
	Age at diagnosis	<1	108	4	3.7	.	.	1	0.9	85	79.4	1	0.9	14	13.1
		1-4	513	28	5.5	7	1.4	3	0.6	462	91.3	3	0.6	100	19.6
		5-9	361	17	4.7	9	2.5	.	.	317	88.5	1	0.3	64	17.8
		10-14	313	15	4.8	6	1.9	2	0.6	228	74.3	1	0.3	35	11.3
		15-20	301	18	6.0	3	1.0	1	0.3	157	53.0	1	0.3	27	9.0
Males	**All cases**		**853**	**47**	**5.5**	**12**	**1.4**	**5**	**0.6**	**694**	**82.4**	**4**	**0.5**	**138**	**16.3**
	Age at baseline	<18	179	13	7.3	2	1.1	2	1.1	156	87.6	2	1.1	45	25.1
		18-19	58	4	6.9	1	1.7	.	.	52	89.7	1	1.7	9	15.5
		20-24	214	11	5.2	3	1.4	1	0.5	179	85.2	1	0.5	42	19.7
		25-29	182	12	6.6	3	1.7	1	0.6	152	84.9	.	.	22	12.2
		30-34	141	4	2.9	2	1.4	.	.	107	77.0	.	.	18	12.9
		35+	79	3	3.8	1	1.3	1	1.3	48	61.5	.	.	2	2.5
	Years since diagnosis	5-9	89	2	2.2	3	3.4	1	1.1	62	71.3	2	2.2	23	25.8
		10-14	264	32	12.1	2	0.8	3	1.1	210	80.5	2	0.8	54	20.5
		15-19	253	6	2.4	4	1.6	.	.	219	88.0	.	.	40	15.9
		20+	247	7	2.8	3	1.2	1	0.4	203	82.9	.	.	21	8.6
	Age at diagnosis	<1	44	2	4.5	.	.	.	.	37	84.1	.	.	7	15.9
		1-4	298	15	5.1	4	1.3	2	0.7	269	91.2	2	0.7	55	18.6
		5-9	203	11	5.4	4	2.0	.	.	176	88.0	1	0.5	40	19.8
		10-14	167	10	6.0	2	1.2	2	1.2	129	78.7	1	0.6	25	15.1
		15-20	141	9	6.4	2	1.4	1	0.7	83	59.7	.	.	11	7.8
Females	**All cases**		**743**	**35**	**4.8**	**13**	**1.8**	**2**	**0.3**	**555**	**75.8**	**3**	**0.4**	**102**	**13.9**
	Age at baseline	<18	134	9	6.8	2	1.5	1	0.8	112	85.5	2	1.5	23	17.3
		18-19	57	4	7.1	.	.	.	.	48	85.7	.	.	11	19.6
		20-24	169	5	3.0	3	1.8	1	0.6	139	82.7	1	0.6	38	22.6
		25-29	172	8	4.7	2	1.2	.	.	127	75.1	.	.	16	9.4
		30-34	126	6	4.8	6	4.8	.	.	87	69.0	.	.	10	7.9
		35+	85	3	3.6	.	.	.	.	42	51.2	.	.	4	4.8
	Years since diagnosis	5-9	76	5	6.7	4	5.3	1	1.3	44	58.7	2	2.7	15	20.0
		10-14	209	12	5.8	1	0.5	.	.	153	74.6	1	0.5	24	11.6
		15-19	246	14	5.7	3	1.2	.	.	198	80.8	.	.	40	16.3
		20+	212	4	1.9	5	2.4	1	0.5	160	77.3	.	.	23	11.1
	Age at diagnosis	<1	64	2	3.2	.	.	1	1.6	48	76.2	1	1.6	7	11.1
		1-4	215	13	6.1	3	1.4	1	0.5	193	91.5	1	0.5	45	21.1
		5-9	158	6	3.8	5	3.2	.	.	141	89.2	.	.	24	15.2
		10-14	146	5	3.5	4	2.8	.	.	99	69.2	.	.	10	6.9
		15-20	160	9	5.7	1	0.6	.	.	74	47.1	1	0.6	16	10.1

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: All bone

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1937**	**223**	**11.6**	**19**	**1.0**	**2**	**0.1**	**1019**	**53.3**	**4**	**0.2**	**384**	**19.9**
	Age at baseline	<18	85	9	10.6	1	1.2	.	.	54	65.1	1	1.2	32	37.6
		18-19	66	12	18.2	.	.	.	.	40	60.6	.	.	19	28.8
		20-24	360	53	14.8	4	1.1	.	.	204	57.3	1	0.3	99	27.7
		25-29	528	66	12.6	3	0.6	.	.	264	51.0	1	0.2	110	20.9
		30-34	521	60	11.6	8	1.5	1	0.2	262	50.9	1	0.2	76	14.7
		35+	377	23	6.2	3	0.8	1	0.3	195	52.3	.	.	48	12.9
	Years since diagnosis	5-9	216	28	13.0	2	0.9	.	.	111	52.6	.	.	51	23.8
		10-14	630	115	18.3	8	1.3	.	.	309	49.7	2	0.3	140	22.3
		15-19	635	53	8.4	5	0.8	1	0.2	339	54.1	2	0.3	126	20.0
		20+	456	27	6.0	4	0.9	1	0.2	260	57.6	.	.	67	14.8
	Age at diagnosis	<1	8	2	25.0	1	12.5	.	.	7	87.5	.	.	5	62.5
		1-4	80	10	12.5	1	1.3	.	.	57	72.2	1	1.3	28	35.0
		5-9	337	34	10.1	1	0.3	.	.	205	61.4	1	0.3	87	25.8
		10-14	776	84	10.9	6	0.8	1	0.1	400	52.2	1	0.1	153	19.9
		15-20	736	93	12.7	10	1.4	1	0.1	350	48.3	1	0.1	111	15.2
Males	**All cases**		**983**	**111**	**11.3**	**11**	**1.1**	**1**	**0.1**	**521**	**53.7**	**3**	**0.3**	**197**	**20.1**
	Age at baseline	<18	43	5	11.6	.	.	.	.	25	58.1	.	.	14	32.6
		18-19	33	4	12.1	.	.	.	.	18	54.5	.	.	7	21.2
		20-24	175	20	11.5	.	.	.	.	101	58.7	1	0.6	50	28.9
		25-29	274	31	11.4	2	0.7	.	.	134	49.8	1	0.4	60	22.0
		30-34	258	38	14.8	6	2.3	.	.	136	53.3	1	0.4	40	15.6
		35+	200	13	6.5	3	1.5	1	0.5	107	53.8	.	.	26	13.1
	Years since diagnosis	5-9	115	12	10.5	.	.	.	.	57	50.9	.	.	29	25.4
		10-14	319	57	17.9	6	1.9	.	.	153	48.6	1	0.3	64	20.2
		15-19	323	30	9.3	1	0.3	.	.	179	55.8	2	0.6	67	20.8
		20+	226	12	5.3	4	1.8	1	0.4	132	59.2	.	.	37	16.4
	Age at diagnosis	<1	4	.	.	.	.	.	.	4	100.0	.	.	2	50.0
		1-4	41	7	17.1	.	.	.	.	29	70.7	.	.	14	34.1
		5-9	172	13	7.6	.	.	.	.	105	61.4	1	0.6	41	23.8
		10-14	364	32	8.8	4	1.1	.	.	191	53.2	1	0.3	74	20.5
		15-20	402	59	14.8	7	1.8	1	0.3	192	48.5	1	0.3	66	16.5
Females	**All cases**		**954**	**112**	**11.8**	**8**	**0.8**	**1**	**0.1**	**498**	**53.0**	**1**	**0.1**	**187**	**19.7**
	Age at baseline	<18	42	4	9.5	1	2.4	.	.	29	72.5	1	2.4	18	42.9
		18-19	33	8	24.2	.	.	.	.	22	66.7	.	.	12	36.4
		20-24	185	33	17.8	4	2.2	.	.	103	56.0	.	.	49	26.6
		25-29	254	35	13.9	1	0.4	.	.	130	52.2	.	.	50	19.8
		30-34	263	22	8.4	2	0.8	1	0.4	126	48.5	.	.	36	13.8
		35+	177	10	5.7	.	.	.	.	88	50.6	.	.	22	12.6
	Years since diagnosis	5-9	101	16	15.8	2	2.0	.	.	54	54.5	.	.	22	22.0
		10-14	311	58	18.8	2	0.6	.	.	156	50.8	1	0.3	76	24.4
		15-19	312	23	7.4	4	1.3	1	0.3	160	52.3	.	.	59	19.2
		20+	230	15	6.6	.	.	.	.	128	56.1	.	.	30	13.2
	Age at diagnosis	<1	4	2	50.0	1	25.0	.	.	3	75.0	.	.	3	75.0
		1-4	39	3	7.7	1	2.6	.	.	28	73.7	1	2.6	14	35.9
		5-9	165	21	12.7	1	0.6	.	.	100	61.3	.	.	46	27.9

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: All bone

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	412	52	12.7	2	0.5	1	0.2	209	51.4	.	.	79	19.3
		15-20	334	34	10.3	3	0.9	.	.	158	48.2	.	.	45	13.6

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Ewings

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**686**	**78**	**11.4**	**5**	**0.7**	**1**	**0.1**	**614**	**91.0**	**4**	**0.6**	**253**	**37.1**
	Age at baseline	<18	54	5	9.3	1	1.9	.	.	41	78.8	1	1.9	25	46.3
		18-19	33	5	15.2	.	.	.	.	26	78.8	.	.	10	30.3
		20-24	157	21	13.5	2	1.3	.	.	139	89.7	1	0.6	65	41.7
		25-29	193	25	13.0	.	.	.	.	180	94.7	1	0.5	80	41.7
		30-34	154	15	9.8	.	.	1	0.7	141	94.0	1	0.7	48	31.6
		35+	95	7	7.4	2	2.1	.	.	87	91.6	.	.	25	26.3
	Years since diagnosis	5-9	91	6	6.7	1	1.1	.	.	60	68.2	.	.	28	31.1
		10-14	231	43	18.6	1	0.4	.	.	218	95.2	2	0.9	101	43.7
		15-19	214	18	8.5	2	0.9	1	0.5	197	94.3	2	0.9	87	41.2
		20+	150	11	7.3	1	0.7	.	.	139	93.3	.	.	37	24.7
	Age at diagnosis	<1	4	1	25.0	1	25.0	.	.	4	100.0	.	.	3	75.0
		1-4	50	5	10.0	1	2.0	.	.	44	89.8	1	2.0	20	40.0
		5-9	169	18	10.7	.	.	.	.	151	90.4	1	0.6	60	35.5
		10-14	258	26	10.2	1	0.4	1	0.4	230	90.9	1	0.4	103	40.4
		15-20	205	28	13.7	2	1.0	.	.	185	91.6	1	0.5	67	32.8
Males	**All cases**		**354**	**40**	**11.3**	**2**	**0.6**	**.**	**.**	**321**	**91.5**	**3**	**0.8**	**131**	**37.1**
	Age at baseline	<18	24	3	12.5	.	.	.	.	19	79.2	.	.	11	45.8
		18-19	17	1	5.9	.	.	.	.	12	70.6	.	.	3	17.6
		20-24	79	9	11.5	.	.	.	.	70	90.9	1	1.3	33	42.3
		25-29	99	9	9.1	.	.	.	.	93	93.9	1	1.0	43	43.4
		30-34	83	13	15.7	.	.	.	.	79	96.3	1	1.2	27	32.5
		35+	52	5	9.6	2	3.8	.	.	48	92.3	.	.	14	26.9
	Years since diagnosis	5-9	49	1	2.1	.	.	.	.	31	66.0	.	.	18	37.5
		10-14	109	18	16.5	.	.	.	.	104	95.4	1	0.9	44	40.4
		15-19	116	13	11.2	1	0.9	.	.	110	94.8	2	1.7	49	42.2
		20+	80	8	10.0	1	1.3	.	.	76	96.2	.	.	20	25.0
	Age at diagnosis	<1	2	.	.	.	.	.	.	2	100.0	.	.	1	50.0
		1-4	26	5	19.2	.	.	.	.	25	96.2	.	.	11	42.3
		5-9	83	6	7.2	.	.	.	.	75	90.4	1	1.2	25	30.1
		10-14	136	13	9.6	.	.	.	.	122	91.0	1	0.7	55	40.7
		15-20	107	16	15.0	2	1.9	.	.	97	91.5	1	0.9	39	36.4
Females	**All cases**		**332**	**38**	**11.5**	**3**	**0.9**	**1**	**0.3**	**293**	**90.4**	**1**	**0.3**	**122**	**37.1**
	Age at baseline	<18	30	2	6.7	1	3.3	.	.	22	78.6	1	3.3	14	46.7
		18-19	16	4	25.0	.	.	.	.	14	87.5	.	.	7	43.8
		20-24	78	12	15.4	2	2.6	.	.	69	88.5	.	.	32	41.0
		25-29	94	16	17.2	.	.	.	.	87	95.6	.	.	37	39.8
		30-34	71	2	2.9	.	.	1	1.4	62	91.2	.	.	21	30.4
		35+	43	2	4.7	.	.	.	.	39	90.7	.	.	11	25.6
	Years since diagnosis	5-9	42	5	11.9	1	2.4	.	.	29	70.7	.	.	10	23.8
		10-14	122	25	20.5	1	0.8	.	.	114	95.0	1	0.8	57	46.7
		15-19	98	5	5.2	1	1.0	1	1.0	87	93.5	.	.	38	40.0
		20+	70	3	4.3	.	.	.	.	63	90.0	.	.	17	24.3
	Age at diagnosis	<1	2	1	50.0	1	50.0	.	.	2	100.0	.	.	2	100.0
		1-4	24	.	.	1	4.2	.	.	19	82.6	1	4.2	9	37.5
		5-9	86	12	14.0	.	.	.	.	76	90.5	.	.	35	40.7

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Ewings

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	122	13	10.7	1	0.8	1	0.8	108	90.8	.	.	48	40.0
		15-20	98	12	12.4	.	.	.	.	88	91.7	.	.	28	28.9

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Osteosarcoma

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1154**	**138**	**12.0**	**14**	**1.2**	**1**	**0.1**	**348**	**30.6**	**.**	**.**	**89**	**7.8**
	Age at baseline	<18	25	3	12.0	.	.	.	.	8	32.0	.	.	2	8.0
		18-19	27	5	18.5	.	.	.	.	10	37.0	.	.	5	18.5
		20-24	184	32	17.4	2	1.1	.	.	51	28.0	.	.	24	13.2
		25-29	317	40	12.7	3	0.9	.	.	72	23.2	.	.	21	6.6
		30-34	340	42	12.4	8	2.4	.	.	106	31.4	.	.	18	5.3
		35+	261	16	6.2	1	0.4	1	0.4	101	39.3	.	.	19	7.4
	Years since diagnosis	5-9	119	22	18.5	1	0.8	.	.	48	41.0	.	.	20	16.9
		10-14	362	67	18.7	7	1.9	.	.	68	19.1	.	.	19	5.3
		15-19	392	34	8.7	3	0.8	.	.	123	31.6	.	.	26	6.7
		20+	281	15	5.4	3	1.1	1	0.4	109	39.4	.	.	24	8.6
	Age at diagnosis	1-4	21	3	14.3	.	.	.	.	6	28.6	.	.	1	4.8
		5-9	151	16	10.6	1	0.7	.	.	44	29.3	.	.	20	13.2
		10-14	492	57	11.7	5	1.0	.	.	149	30.6	.	.	38	7.8
		15-20	490	62	12.8	8	1.6	1	0.2	149	31.0	.	.	30	6.2
Males	**All cases**		**581**	**67**	**11.6**	**9**	**1.6**	**1**	**0.2**	**173**	**30.2**	**.**	**.**	**46**	**8.0**
	Age at baseline	<18	18	2	11.1	.	.	.	.	5	27.8	.	.	2	11.1
		18-19	12	2	16.7	.	.	.	.	4	33.3	.	.	2	16.7
		20-24	86	11	12.8	.	.	.	.	23	27.1	.	.	12	14.1
		25-29	165	21	12.8	2	1.2	.	.	36	22.5	.	.	12	7.3
		30-34	161	23	14.4	6	3.8	.	.	49	30.8	.	.	8	5.0
		35+	139	8	5.8	1	0.7	1	0.7	56	40.6	.	.	10	7.2
	Years since diagnosis	5-9	64	11	17.2	.	.	.	.	26	41.3	.	.	10	15.6
		10-14	191	35	18.4	6	3.2	.	.	36	19.3	.	.	8	4.2
		15-19	192	17	8.9	.	.	.	.	61	32.1	.	.	14	7.3
		20+	134	4	3.0	3	2.3	1	0.8	50	37.9	.	.	14	10.5
	Age at diagnosis	1-4	11	1	9.1	.	.	.	.	2	18.2	.	.	1	9.1
		5-9	76	7	9.2	.	.	.	.	22	29.3	.	.	11	14.5
		10-14	221	19	8.6	4	1.8	.	.	64	29.4	.	.	17	7.8
		15-20	273	40	14.8	5	1.8	1	0.4	85	31.7	.	.	17	6.3
Females	**All cases**		**573**	**71**	**12.5**	**5**	**0.9**	**.**	**.**	**175**	**30.9**	**.**	**.**	**43**	**7.6**
	Age at baseline	<18	7	1	14.3	.	.	.	.	3	42.9	.	.	.	.
		18-19	15	3	20.0	.	.	.	.	6	40.0	.	.	3	20.0
		20-24	98	21	21.4	2	2.0	.	.	28	28.9	.	.	12	12.4
		25-29	152	19	12.7	1	0.7	.	.	36	24.0	.	.	9	5.9
		30-34	179	19	10.6	2	1.1	.	.	57	31.8	.	.	10	5.6
		35+	122	8	6.7	.	.	.	.	45	37.8	.	.	9	7.6
	Years since diagnosis	5-9	55	11	20.0	1	1.8	.	.	22	40.7	.	.	10	18.5
		10-14	171	32	18.9	1	0.6	.	.	32	18.9	.	.	11	6.4
		15-19	200	17	8.5	3	1.5	.	.	62	31.2	.	.	12	6.0
		20+	147	11	7.6	.	.	.	.	59	40.7	.	.	10	6.9
	Age at diagnosis	1-4	10	2	20.0	.	.	.	.	4	40.0	.	.	.	.
		5-9	75	9	12.0	1	1.3	.	.	22	29.3	.	.	9	12.0
		10-14	271	38	14.1	1	0.4	.	.	85	31.6	.	.	21	7.8
		15-20	217	22	10.3	3	1.4	.	.	64	30.0	.	.	13	6.1

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.